^
Association details:
| Biomarker: | Chr amplification(9)(p24.1) |
|---|---|
| Cancer: | Hodgkin Lymphoma |
| Drug: | Opdivo (nivolumab) (PD1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
THE PROGNOSTIC VALUE OF PD-L1 AND PD-L2 LOCI ALTERATIONS IN PATIENTS WITH RELAPSED/REFRACTORY HODGKIN LYMPHOMA TREATED WITH NIVOLUMAB
Published date:
05/12/2021
Excerpt:
The aim of the current study was to investigate the prevalence and the type of 9p24.1 alterations in severely the pretreated population of r/r cHL patients receiving nivolumab (nivo)...for 9p24.1 amplification, a 3-year PFS was 20% (95% CI 3.1- 47%) with median of 20.6 months (95% CI 6.6-35.6)...